Overview

Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to develop a nasal model for influenza infection using the live attenuated influenza vaccine (LAIV). The investigators will administer LAIV to healthy adult volunteers in order to simulate influenza infection, and obtain nasal specimens to measure influenza virus and inflammatory/immune responses.
Phase:
Phase 4
Details
Lead Sponsor:
University of Alabama at Birmingham
Treatments:
Vaccines